학술논문
BASIC AND CLINICAL STUDIES ON CEFOTIAM HEXETIL, A NEW ORAL CEPHALOSPORIN ANTIBIOTIC, IN THE SURGICAL FIELD / 外科領域における新経口用セファロスポリン剤Cefotiam hexetilの基礎的, 臨床的検討
Document Type
Journal Article
Author
AKIRA HORIKAWA; HIROKO SAKAI; HISASHI FURUHATA; IZUMI SATO; KANEAKI MATSUSHITA; KOUMEI KATO; MASAHIKO KUNIMATSU; MASAMU KAJIWARA; MASASHI FUJII; MIKIHIRO TOMINAGA; REI ANRAKU; SHIGETOMI IWAI; TAKASHI OOSAWA; TAKASHI SAKABE; TAKESHI SATO; TOORU NISHIKAWA; YOSHIAKI CHISHIMA; 佐藤 いづみ; 佐藤 毅; 加藤 高明; 千島 由朗; 古畑 久; 国松 正彦; 坂部 孝; 堀川 明; 大沢 崇; 安楽 勵; 富永 幹洋; 岩井 重富; 松下 兼昭; 梶原 優; 藤井 雅志; 西川 亨; 酒井 弘子
Source
CHEMOTHERAPY. 1988, 36(Supplement6):655
Subject
Language
Japanese
ISSN
0009-3165
1884-5894
1884-5894
Abstract
We performed basic and clinical studies on cefotiam hexetil (CTM-HE), a new oral cephalosporin, and obtained the following results.Antibacterial activity of CTM-HE against clinical isolates was compared with those of ampicillin (ABPC), cephalexin (CEX), cefaclor (CCL), lincomycin (LCM), clindamycin (CLDM), minocycline (MINO), norfloxacin (NFLX) and ofloxacin (OFLX). MICS of cefotiam hexetil were determined against clinical isolates of coagulase-positive and-negative staphylococci, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae and Bacteroides fragilis. The drug showed good activity against staphylococci, but less so against E. faecalis. It also demonstrated excellent activity against E. coli, good activity against K. pneumoniae, but less against B. fragilis. In the clinical study, cefotiam hexetil was administered to 20 patients with infections mainly of the skin and soft tissue. Clinical response was good enough in 16 cases (80.0%) and poor in 4. No serious side effects were noted except one case of diarrhea.